Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2017

View Archived Issues

Eisai updates pipeline progress of second quarter of fiscal 2017

Mitsubishi Tanabe Pharma reports development activities of second quarter of fiscal 2017

Bio-Path Holdings selects third drug candidate, gives update on discovery efforts

FDA clears IND for micro-dystrophin gene therapy program in DMD

USAN approves asalhydromorphone as nonproprietary name for KemPharm's KP-511

Clinical results encourage use of [68Ga]DATATOC for imaging neuroendocrine tumors

Novel tracer targets angiomotin for brain tumor imaging

FDA gives orphan status to Achillion's ACH-4471 for PNH

Donaperminogene seltoplasmid accepted as generic name for ViroMed's VM-202

NINJ2 gene linked to treatment response in multiple sclerosis

Memantine improves red blood cell parameters, quality of life in sickle cell patients

FDA grants orphan drug designation to arimoclomol for inclusion body myositis

KB-103 granted orphan drug designation by the FDA

GSK submits sBLA for mepolizumab as add-on to maintenance treatment of eosinophilic COPD

FDA approves Keryx's Auryxia in new indication

AstraZeneca patents new ERalpha antagonists and SERDs

Shenzhen Targetrx Biotechnology identifies PARP inhibitors

Merck & Co. presents compounds for HCV infection treatment

Novel NLRP3 agonists presented by IFM Therapeutics

Fraunhofer-Gesellschaft patents meprin inhibitors

Alnylam Pharmaceuticals begins phase III ENVISION study of givosiran

Batu Biologics receives IND approval from FDA for phase I trials of ValloVax

Appili Therapeutics wins grant from U.S. Department of Defense for antibiotic program

Kite Pharma initiates phase I study of KITE-585 in relapsed/refractory multiple myeloma

SiteOne Therapeutics receives grant from U.S. Department of Defense

DSMB clears ReNeuron's retinitis pigmentosa trial to advance into phase II

U.S. Environmental Protection Agency registers mosquito biopesticide

Seres Therapeutics awarded grant from CARB-X to support SER-155 development

Preliminary results from first in human trial of cystic fibrosis candidate GLPG-2737

Cellectar Biosciences gives update on phase I study of CLR-131 in multiple myeloma

Ultragenyx completes acquisition of Dimension Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...